Skip to main content
. 2019 Mar 3;10(7):1611–1615. doi: 10.7150/jca.29106

Table 2.

Best overall response rate (RR) and disease control rate (DCR) in patients receiving regorafenib

Total
N (%)
LC
N (%)
RC
N (%)

p-value*
Response rate
(above PR)
4 (3.0%) 4 (4.0%) 0 (0.0%) 0.573
Disease control rate
(above SD)
41 (30.4%) 34 (34.0%) 7 (20.0%) 0.092
PR 4 (3.0%) 4 (4.0%) 0 (0.0%)
SD 37 (27.4%) 30 (30.0%) 7 (20.0%)
PD 90 (66.7%) 62 (62.0%) 28 (80.0%)
Not evaluable 4 (3.0%) 4 (4.0%) 0 (0.0%)

* p value is calculated by chi-square test.